Patent intelligence · US
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
Patent details — US 12397034
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 26, 2025
- Expiration
- Aug 21, 2045
- Applicant
- China Medical University
- Claims
- 2
- CPC classes
- A61K, A61K31/05, A61K31/11, A61K31/7034
Quick answer
US 12397034 (Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons) is held by China Medical University. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- China Medical University
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K31/05, A61K31/11, A61K31/7034, A61K31/7076, A61K36/8988
More from China Medical University
Related pharmaceutical patents in our USPTO index.
-
US 12427137
Method for reducing methane production in animal stomach
granted -
US 12421269
SGLT2/DPP4 inhibitor and application thereof
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12389931
Oyster peptide with effect of improving sexual function and preparation method thereof
granted -
US 12383535
Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
granted -
US 12378241
Pyridine derivative as FGFR and VEGFR dual inhibitors
granted -
US 12371434
MLL1 inhibitors and anti-cancer agents
granted
Frequently asked questions
What is US patent 12397034?
US 12397034 (Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons) is held by China Medical University. Status: granted. Granted Aug 26, 2025. Expires Aug 21, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12397034?
China Medical University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.
When does US 12397034 expire?
Our index shows an expiration date of Aug 21, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.